Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

6533b7d9fe1ef96bd126b8bf

RESEARCH PRODUCT

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

A C Wotherspoon Andrés Cervantes Jens C. Hahne Zakaria Eltahir Clare Peckitt D. Gonzalez De Castro S. Hulkki Wilson Diana Tait Ruwaida Begum Andrea Lampis Ian Chau Francesco Sclafani Nicola Valeri Nicola Valeri Chiara Braconi Chiara Braconi Gina Brown Jacqui Oates David Cunningham Bengt Glimelius Josep Tabernero

subject

Male Oncology Organoplatinum Compounds Colorectal cancer medicine.medical_treatment LET-7 MICRORNA-BINDING Cetuximab medicine.disease_cause COLORECTAL-CANCER 3'-UNTRANSLATED REGION 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Rectal cancer Neoadjuvant therapy Single-nucleotide polymorphism 0303 health sciences Cetuximab COLON-CANCER Hazard ratio CAPOX Regimen Chemoradiotherapy Hematology single-nucleotide polymorphism Middle Aged Combined Modality Therapy Neoadjuvant Therapy BINDING SITE POLYMORPHISM 3. Good health Oxaliplatin Let-7 Oncology 030220 oncology & carcinogenesis 5-FLUOROURACIL /dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being Female KRAS Life Sciences & Biomedicine medicine.drug Adult Genetic Markers medicine.medical_specialty Genotype LCS-6 KRAS variant Polymorphism Single Nucleotide Disease-Free Survival CLINICAL-TRIAL Proto-Oncogene Proteins p21(ras)03 medical and health sciences SDG 3 - Good Health and Well-being let-7 Internal medicine Gastrointestinal Tumors Biomarkers Tumor KRAS medicine Humans Oncology & Carcinogenesis Progression-free survival rectal cancer neoplasms Capecitabine Aged 030304 developmental biology Cancer och onkologi Science & Technology Rectal Neoplasms business.industry Original Articles medicine.disease digestive system diseases MicroRNAs Cancer and Oncology business 1112 Oncology And Carcinogenesis Chemoradiotherapy RAS

description

KRAS mutation has been reported as a marker of radio-resistance in rectal cancer and unfavourable outcome in both colon and rectal cancer. This study suggests that a single-nucleotide polymorphism of the KRAS gene (LCS-6 variant) may predict response to neoadjuvant treatment and mitigate the poor prognosis associated with KRAS mutation in locally advanced rectal cancer.

year	journal	country	edition	language
2015-09-01	Annals of Oncology

https://doi.org/10.1093/annonc/mdv285